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Background: The aim was to evaluate the presence of meta-
bolic bone disease (MBD) in patients with Crohn’s disease (CD)
and to identify potential etiologic factors.
Methods: The case–control study included 99 patients with CD
and 56 controls with a similar age and gender distribution. Both
groups had dual-energy x-ray absorptionmetry and a nutritional
evaluation. Single nucleotide polymorphisms at the IL1, TNF-a,
LTa, and IL-6 genes were analyzed in patients only. Statistical
analysis was performed using SPSS software.
Results: The prevalence of MBD was signiﬁcantly higher in
patients (P ¼ 0.006). CD patients with osteoporosis were older (P
< 0.005), small bowel involvement and surgical resections were
more frequent (P < 0.005), they more often exhibited a penetrat-
ing or stricturing phenotype (P < 0.05), duration of disease
over 15 years (P < 0.005), and body mass index (BMI) under
18.5 kg/m2 (P < 0.01) were more often found. No association
was found with steroid use. Patients with a Z-score < 2.0 more
frequently had chronic active disease (P < 0.05). With regard to
diet, low vitamin K intake was more frequent (P ¼ 0.03) and
intake of total, monounsaturated, and polyunsaturated fat was
higher in patients with Z-score < 2.0 (P < 0.05). With respect
to genetics, carriage of the polymorphic allele for LTa252 A/G
was associated with a higher risk of osteoporosis (P ¼ 0.02).
Regression analysis showed that age over 40 years, chronic active
disease, and previous colonic resections were independently asso-
ciated with the risk of developing MBD.
Conclusions: The prevalence of MBD was signiﬁcantly higher
in CD patients. Besides the usual risk factors, we observed that
factors related to chronic active and long-lasting disease increased
the risk of MBD.
(Inﬂamm Bowel Dis 2010;16:2117–2124)
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M etabolic bone disease (MBD), including osteopeniaand osteoporosis, is frequently observed in patients
with Crohn’s disease (CD),1,2 but the pathogenesis of this
common complication remains under discussion. Chronic
inﬂammation, prolonged use of steroids, as well as low
intake of calcium and vitamin D are among the most
frequently implicated factors.2–5 In a previous case–control
study that included 78 patients with CD6 we observed that
a large proportion of patients had a restrictive diet in terms
of dairy products and well as of vegetables and fruits,
which resulted in a signiﬁcantly lower intake of calcium,
vitamin D, and vitamin K, as compared to controls, all
these nutrients being fundamental for bone metabolism.7 In
that same study we observed that patients with CD pre-
sented a signiﬁcantly lower body mass index (BMI) as
compared to controls and the prevalence of sedentarism
was also higher in CD patients.6 These latter are also risk
factors for MBD.
There is also evidence that chronic inﬂammation per
se has a deleterious effect on bone mass2 and control of
disease activity with modern biologic therapy results in an
improvement of bone mineral density.9
Other investigators have focused on the role that
genetic factors might play in the pathogenesis of this com-
plication. There is now evidence that CD results from an
imbalance between pro- and antiinﬂammatory cytokines,
where the ﬁnal result is a chronic and inappropriate
inﬂammatory response to usual endoluminal stimuli such
as bacterial ﬂora and luminal nutrients.10,11 Previous stud-
ies showed that besides systemic inﬂammatory response,
IL1 and IL-6 proinﬂammatory cytokines play a fundamen-
tal role in the paracrine stimulation of osteoclasts, thereby
inﬂuencing the process of bone reabsorption.12,13 In a pre-
vious study Schulte et al14 observed that noncarriage of the
Received for publication February 23, 2010; Accepted February 24,
2010.
From the *Instituto Portugueˆs de Oncologia Francisco Gentil, Lisboa,
Portugal, †Escola Superior de Tecnologias da Sau´de, Lisboa, Portugal,
‡Hospital de Santa Maria, EPE, Lisboa, Portugal.
Supported in part by a grant from Sociedade Portuguesa de
Gastrenterologia.
Reprints: Marı´lia Cravo, MD, PhD, Servic¸o de Gastrenterologia,
Instituto Portugueˆs de Oncologia Francisco Gentil, Rua Professor Lima
Basto, 1093 Lisboa codex, Portugal (e-mail: marilia.cravo@sapo.pt)
Copyright VC 2009 Crohn’s & Colitis Foundation of America, Inc.
DOI 10.1002/ibd.21297
Published online 28 April 2010 in Wiley Online Library
(wileyonlinelibrary.com).
Inﬂamm Bowel Dis  Volume 16, Number 12, December 2010 2117
240-basepair allele of the IL-1ra gene and carriage of the
130-basepair allele of the IL-6 were independently associ-
ated with increased bone loss. These observations further
reinforce the hypothesis that systemic inﬂammation might
also intervene in the pathogenesis of MBD in patients
with CD.
The aims of the present study were to 1) evaluate the
prevalence of MBD in a group of patients with CD as com-
pared to a group of healthy controls matched for age and
sex, and 2) to analyze potential etiologic factors, namely,
disease characteristics, therapies used for CD, nutritional
status, dietary intake, and genetic polymorphisms of cyto-
kine genes.
PATIENTS AND METHODS
The study protocol was approved by the Ethics and
Scientiﬁc Committees from both the Instituto Portugues de
Oncologia Francisco Gentil (IPOFG) and from the Univer-
sity Hospital de Santa Maria, both located in Lisbon, Portu-
gal. All subjects provided informed and written consent
before entering the study.
Ninety-nine consecutive outpatients with a conﬁrmed
diagnosis of CD who were on a routine visit to the outpa-
tient clinic during the period between September 2004 until
November 2007 were asked to participate in the study. The
diagnosis was based on previously deﬁned criteria16 and
disease activity was assessed according to the Harvey–
Bradshaw Index (HBI).17 None of the patients were on ste-
roids at the time of the study and none were hospitalized.
Only patients with mild to moderate disease (HBI <7)
were included. According to the HBI, 36/99 (36.4%) of
patients had moderately active disease with an HBI 4,
whereas the remaining 63 (63.6%) had inactive disease.
These activity indices refer to at least 3 months/year.
Patients with severe active disease (HBI >7) at the time of
patient inclusion or with need of systemic steroids were
excluded (n ¼ 7). All patients had a stable body weight
during the 3 months preceding the study. The control group
included 56 healthy individuals, with a similar age and
gender distribution (Table 1).
Physical activity was assessed using Jackson’s ques-
tionnaire,18 which categorized subjects in three different
levels: low (0), intermediate (1), and high (2). To improve
statistical power and because physical activity was not
evaluated in some patients and controls, we considered
physical activity on two levels: sedentary versus intermedi-
ate/active.
Bone Mineral Density (BMD) Assessment
BMD was measured by dual-energy x-ray absorption-
metry (DXA) at the lumbar spine (second, third, fourth ver-
tebrae) and at the proximal femur, both in patients and
controls. All procedures were performed at two radiologic
centers for patient convenience. Reference values for men
and women were supplied by Lunar Corp., referring to a
normal white north European population (2588 white
women and men aged 20–79 years).19,20 According to
WHO, measurement of BMD by DXA is the ‘‘gold-stand-
ard’’ noninvasive method for the diagnosis of osteoporo-
sis.21 The presence of MBD is deﬁned using the number of
standard deviations (SDs) from normal values of a young
reference population, which is the T-score. A T-score lower
than 2.5 is diagnostic for osteoporosis while a T-score
between 2.5 and 1.0 means osteopenia. In contrast, the
Z-score is a comparison of the patient’s BMD to an age-
matched population. A Z-score of 2.0 or lower is consid-
ered below the expected range for age and should prompt
careful scrutiny for coexisting problems that may contrib-
ute to osteoporosis.22 In the present study we considered
both T-score lower than 2.5 and Z-score lower than 2.0
as diagnostic for the presence of MBD, as the clinical sig-
niﬁcance of osteopenia is debatable.
Dietary Intake
Dietary intake was assessed using a semiquantitative
food-frequency questionnaire, validated to the Portuguese
population,23 consisting of 86 food items with nine possible
TABLE 1. Demographic, Nutritional, and Osteodensitom-
etry Analysis in Patients and Controls
Patients
(n ¼ 99)
Controls
(n ¼ 56) P
Age 40614 42610 0.35
Gender –
F/M 62/37 37/19 0.66
Physical activity
Yes/No 40/59 19/37 0.35
Smoking
Yes/No 50/49 12/44 0.000
BMI (m6SD) 24.564.4 24.364.1 0.85
BMI (kg/m2) (n)
<18.5 5/99 2/56
19–25 58/99 33/56
> 25 36/99 21/56 0.69
BMD – L 1.23 6 0.5 1.15 6 0.18 0.18
BMD – F 0.94 6 0.31 0.98 6 0.17 0.31
T-score L 1.12 6 1.13 0.35 6 1.20 0.000
T-score F 0.88 6 1.06 0.38 6 1.06 0.01
DXA
Normal 53 (54%) 44 (80%)
Osteopenia 28(28%) 9 (14%)
Osteoporosis 18 (17%) 3 (5%) 0.006
Z-score < 2.0 7 (8%) 1 (2%) 0.21
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answers with respect to the medium frequency intake
(never or less than once a month, to six or more than six
times a day); and three possible answers with regard to the
size of the portion (smaller, equal, or larger than the
medium portion size). Dietary intake was analyzed with a
modiﬁed database Food Processor Plus software, v. 7
(ESHA Research, Salem, OR), which includes some Portu-
guese food items and allows the quantiﬁcation of different
macro- and micronutrients. Patients were asked to recall
their dietary habits during the year prior to interview. In
all, 44/99 patients were taking vitamin supplements: 23
were taking folate (1 mg / 3 times/week) and the remaining
21 patients were on a multivitamin supplement.
Genotype Data
Whole blood samples from CD patients were col-
lected and kept at 20C until use. DNA extraction was
performed with phenol/chloroform extraction. Polymerase
chain reaction (PCR) and restriction fragment length poly-
morphism (RFLP) techniques were used to analyze gene
polymorphisms in the IL-1, TNF-a, LTa, and IL-6 genes.
For the PCR reaction mixture, with a ﬁnal volume of 20
lL, we utilized 2 lL of reaction buffer ([Taq buffer
þ(NH4)2SO2] 10), 2 lL MgCl2 (25 mM), 2 lL dNTPs
(2 mM), 0.66 lL of each primer (6 lM), 0.1 lL of Taq
DNA polymerase, 1–4 lL of DNA depending on whether
DNA was obtained from whole blood or through the
Generation Capture Card Kit, and H2O until ﬁnal volume.
The primers in use were for IL1b-511 C/T (F: 50-CCCAG
CCAAGAAAGGTCAAT-30/R: 50-GTGGGACAAAGTGGA
AGACA-30), for IL1b þ3953C/T (F: 50-TCCCAGCTTCAT
CCCTACTG-30/ R:30-TGGAGGTGGAGAGCTTTCAG-30),
for TNF-a 857C/T (F: 50-AAGTCGAGTATGGGGACCC
CCCGTTAA-30/R: 50-TTTCATTCTGACCCGGAGAC-30),
for TNF-a 308 G/A (F: 50-AGGCAATAGGTTTTGAGG
GCCAT-30/R: 50-AAAGTTGGGGACACACAAGC-30), for
LTA þ252 A/G (F:50-GCTTCGTGCTTTGGACTACC-30/
R: 50-AAGGTGAGCAGAGGGAGACA-30), and for IL-6
174G/C (F: 50-TGCACTTTTCCCCCTAGTTG-30/R:
50-GCCTCAGACATCTCCAGTCC-30). IL1Ra is a VNTR
of 86 bp. The following ampliﬁcation protocol was used:
denaturation at 95C for 5 minutes, followed by 35 cycles
of denaturation at 95C for 45 seconds, annealing at 60C
for 30 seconds, and extension at 72C for 1 minute, with a
ﬁnal extension step at 72C for 10 minutes. The RFLP
reaction mixture, with a ﬁnal volume of 30 lL, consisted
of 3 lL of appropriate reaction buffer (10) (New England
Biolabs, Beverly, MA), 0.5 lL of DdeI (IL1b 511C/T),
NcoI (TNF-a 308G/A), HincII (TNF-a 857C/T), HinfI
(LTa þ252A/G), and NlaIII (IL-6), 1 lL of BseYI (LTa
þ80C/A) and 0.25 lL of TaqI (IL1b þ3953C/T) (New
England Biolabs), 0.3 lL BSA for speciﬁc enzymes (TaqI,
HincII, NlaIII) and H2O until ﬁnal volume. The reaction
took place for 2 hours at 37C for all polymorphisms
except for IL1b þ3953C/T, which was carried out at 65C.
After digestion the product was run on a 4% gel and geno-
types for each subject were recorded.
Statistical Methods
Statistical analysis was performed using SPSS v. 16.0
for Windows (Chicago, IL; EUA 2007) and included stand-
ard descriptive statistics, partial correlation, and multiple
regression. Data were expressed as mean 6 SD, as number
of subjects and (percentage), or as odds ratio (OR) and
95% conﬁdence interval (CI). Bivariate analyses were con-
ducted using Student’s t-test or Mann–Whitney test for
continuous and chi-square for categorical variables. Multi-
ple regression analysis was used to examine the independ-
ent effects of demographic factors, disease characteristics,
medications used to treat CD, nutritional status, and intake
on the existence of MBD. On multivariate analysis, regres-
sion models were adjusted for age and sex distribution,
smoking habits, BMI, and steroid use. Statistical signiﬁ-
cance was established for P < 0.05.
RESULTS
In Table 1 we show patient and control characteris-
tics in terms of gender and age distribution, exercise and
smoking habits, BMI, and DXA data. As shown, no signiﬁ-
cant differences were observed with respect to age and
gender distribution, nor with respect to physical activity.
However, a signiﬁcantly higher proportion of patients were
smokers (P < 0.0001). BMI was similar in patients and
controls. BMD, both lumbar and femoral, were similar, but
Z- and T-scores both in the spine and in the femur were
signiﬁcantly lower in patients. Accordingly, the prevalence
of osteopenia was double in patients, while that of osteopo-
rosis was more than 3 times as prevalent in patients as
compared to controls.
As demographic distribution was similar in controls
and patients, we tried to identify other possible factors that
could explain the presence of MBD only in a subgroup of
patients with CD. Table 2 shows patients and disease char-
acteristics considering T-scores lower or higher than 2.5
and Z-score lower or higher than 2.0. If we consider a T-
score lower than 2.5, we observed that older age, small
bowel involvement, a penetrating or a structuring pheno-
type, previous surgical resections, and duration of disease
greater than 15 years were all directly and signiﬁcantly
associated with the presence of osteoporosis. In contrast,
previous steroid intake evaluated as total number of steroid
pulses, number pulses/year of disease, or steroids during
the previous year did not show any signiﬁcant association
with the presence of osteoporosis (Table 2). The same
applies to the practice of physical exercise or smoking hab-
its. With respect to therapies used, we observed that the
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use of azathioprine, which was present in 65/99 patients,
was a protective factor regarding the presence of osteopo-
rosis (P ¼ 0.006). With regard to inﬂiximab use no signiﬁ-
cant associations were observed (P ¼ 0.96), although the
number of patients treated with this drug was far too small
to allow any deﬁnitive conclusions. However, 11/13 of the
patients treated with inﬂiximab did not have osteoporosis.
When we considered patients with a Z-score lower or
higher than 2.0, the results were similar, although some
differences did not reach statistical signiﬁcance probably
due to the fact that there were only seven patients with a
Z-score < 2.0. Interestingly, the disease activity index,
which did not show any signiﬁcant association for the pres-
ence of osteoporosis, was now signiﬁcantly associated with
a lower Z-score (Table 2). With smoking habits and physi-
cal activity no signiﬁcant associations were observed.
When analyzing the association between MBD and
the presence of polymorphic alleles either in homo- or
TABLE 2. Clinical Features of CD Patients With or Without MBD
T-score Z-score
< 2.5 > 2.5 <2.0 >2.0
Mean age 54.2 616.6 38.5 613.0** 50.7 610.7 40.0 614.8*
Age
< 40 years 15% 59% 14% 55%
 40 years 85% 41%** 86% 45%*
Gender (F/M) 9/5 23/44 6/1 26/40
Disease location
Small bowel 61% 25% 43% 28%
Ileocolonic 31% 57% 43% 54%
Colonic 8% 18%* 14% 18%
Phenotype
Inﬂammatory 8% 31% 14% 24%
Penetrating 39% 34% 43% 38%
Stricturing 54% 35%* 43% 38%
Age at diagnosis
< 40 years 54% 88% 81% 47%
 40 years 46% 12%** 19% 53%
Duration of disease
 15 years 69% 29% 43% 35%
< 15 years 31% 71%** 57% 65%
Previous surgeries (%) 77% 42%* 57% 49%
Small bowel surgeries (n) 3.563.8 0.862.0** 1.561.2 1.362.7
Colonic surgeries 4.064.4 0.561.9** 0.560.57 1.262.9
Steroids past year (%) 31% 38% 29% 37%
# Pulses steroids (n) 6.8612 3.463.8 4.765.5 3.966.3
# Pulses steroids/year (n) 0.560.8 0.360.3 0.260.2 0.360.4
Use of budesonide (n¼43) 30% 16% 50% 16%
Use of azathioprine (n¼65) 54% 87%** 57% 83%
Use of biologics (n¼13) 17% 16% 33% 15%
Harvey-Bradshaw index
4 46% 69% 28% 69%
4–7 54% 31% 72% 31%*
Physical activity
Yes 63% 55% 59% 59%
Smoking habits
Yes 50% 50% 50% 55%
*P < 0.05.
**P < 0.005.
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heterozygosity for the several cytokine genes analyzed, we
observed that patients who carried the polymorphic allele
for LTa252 A/G had a higher risk of presenting osteoporo-
sis (P ¼ 0.02), although the risk of having a Z-score <
2.0 did not reach statistical signiﬁcance (P ¼ 0.08). Also
patients carrying the polymorphic allele of IL1Ra, the sole
anti-inﬂammatory cytokine studied, had a tendency to pres-
ent with a Z-score lower than 2.0 (P ¼ 0.06).
Table 3 shows nutritional status and nutrient intake
in patients with or without bone disease. Although mean
BMI was not signiﬁcantly different in the patients with
and without MBD, we observed that a higher proportion
of patients with MBD were malnourished (BMI <18.5 kg/
m2). No differences were observed with respect to energy,
protein, or carbohydrate intake (data not shown). However,
signiﬁcant differences were observed with respect to
amount and type of fat intake when considering patients
with a Z-score lower or higher than 2.0. Very interest-
ingly, we observed that total fat intake, monounsaturated
and n6, n3 polyunsaturated fat intake was signiﬁcantly
higher in patients with a Z-score < 2.0. Monounsaturated
n9 fat intake was also higher in this group of patients but
not signiﬁcantly so, probably due to the large SDs observed
(81 6 78 versus 47 6 39 g/day; P ¼ 0.12). Calcium and
vitamin D intakes were low in both groups of patients;
48% and 54% of patients had a low intake of calcium and
vitamin D, respectively, according to the RDI values. Vita-
min K intake was also under RDI in 50.6% and this pro-
portion was signiﬁcantly higher in patients with osteoporo-
sis (P ¼ 0.03).
Table 4 shows by univariate analysis which factors
were associated with higher or lower risk of presenting a
T-score lower than 2.5 or a Z-score lower than 2.0.
Older individuals, at diagnosis, longer duration of disease,
more severe disease with higher HBI scores, and a higher
number of previous surgeries were all risk factors for
MBD. From a nutritional point of view, low intake of vita-
min K and high intake of monounsaturated fat were the
sole variables displaying a signiﬁcant association with
the risk of MBD. Carriers of the polymorphic allele for the
LTa 252 A/G polymorphism were also at increased risk of
osteoporosis. On multivariate analysis (Table 5) and adjust-
ing for age and sex distribution, smoking habits, BMI,
and previous steroid use, which are factors commonly
TABLE 3. Nutritional Characteristics of Patients With or Without MBD
T-score Z-score
< 2.5 > 2.5 <2.0 >2.0
BMI (kg/m2) 23.564.3 24.964.5 23.4þ3.7 24.864.6
BMI < 18.5 kg/m2 23% 3%** 29% 3%**
Total fat (g/d) 82.0632.7 80.3627.6 101.9629.1 78.2629.1*
Saturated fat (g/d) 26.0611.2 26.5610.6 29.9610.8 25.9611.1
Monounsaturated fat (g/d) 36.1615.3 34.8612.2 46.4610.8 33.7612.9**
N9 fatty acids (g/d) 61.7651.5 46.1637.4 81.5678.0 47.0639.1
PUFA n6, n3 (g/d) 13.066.5 12.365.0 17.367.1 12.065.1*
Vitamin D (lg/d) 19.7626.9 19.0647.8 19.9628.2 19.1646.5
Vitamin K (lg/d) 10.068.9 14.0613.1* 12.9610.9 13.4612.9
Calcium (mg/d) 6926652 7456490 7336723 7146495
*P < 0.05.
**P < 0.01.
TABLE 4. Univariate Analysis for Factors Inﬂuencing the
Presence of a T-score Lower than 2.5 or a Z-score
Lower than 2.0
T-score < 2.5 Z-score < 2.0
OR, CI 95% OR, CI 95%
Duration of disease >
15 years
5.88 (1.6–21.5) 1.50 (0.3–7.2)
Age > 40 years old 8.25 (1.6–40.3) 7.94 (0.9–69.3)
Age at diagnosis > 40
years old
6.1 (1.6–22.8) 4.16 (0.8–21.6)
HBI  4 points 2.82 (0.8–9.5) 6.0 (1.1–33.8)
LTAþ 252 A/G
(carriers)
3.84 (1.1–13.8) 3.71 (0.7–20.4)
BMI > 18.5 kg/m2 0.11 (0.02–0.71) 0.07 (0.01–0.62)
Small bowel surgeries 11.6 (2.1–63.3) 6.38 (0.6–66.2)
Colonic surgeries 20.6 (3.6–118.2) 2.85 (0.4–22.3)
Vitamin K intake >
RDI
0.24 (0.06–0.96) 0.38 (0.7–2.1)
Increased intake of
Monounsaturated fat
2.79 (0.8–9.9) 1.22 (1.1–1.4)
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inﬂuencing the presence of MBD in the general population,
we observed that only age above 40 years old, chronic
active disease with HBI 4, and previous colonic surgeries
were signiﬁcantly associated with the presence of MBD.
DISCUSSION
MBD has long been described as a complication of
inﬂammatory bowel disease, mainly of CD, although the
prevalence and the etiologic factors responsible for this
complication remain under discussion.1–4 It is also debata-
ble which is the most appropriate method to evaluate the
presence of MBD in this group of patients. In the present
study, DXA was used because it is the method recom-
mended in the last consensus published by ECCO (Euro-
pean Crohn’s and Colitis Organization).24 Because the clin-
ical signiﬁcance of osteopenia is unknown, since it does
not inevitably progresses to osteoporosis, in the present
study we used as the gold standard for the diagnosis of
MBD the presence of osteoporosis (T-score < 2.5),
which is clearly associated with an increased risk for frac-
ture, or a Z-score lower than 2.0. The latter should
prompt the identiﬁcation of other coexisting problems
which could contribute to osteoporosis, as recently sug-
gested by the ISCD (International Society for Clinical Den-
sitometry).22 Since in the present study we were aiming at
identifying potential etiologic factors that could be respon-
sible for the presence of MBD in certain patients with CD
but not in others, this parameter appeared particularly suita-
ble for that purpose.
Previous studies have shown a prevalence of osteope-
nia and osteoporosis of 50% and 30%, respectively, but
the numbers vary widely.2 One reason for these discrepan-
cies may be related to the fact that most of these studies
do not include a control group. Because MBD is highly
prevalent in the general population, in the present study we
included a control group with a similar age and gender dis-
tribution, so that the magnitude of the problem could be
more realistic. In comparison to our control group, we
observed that our patient population had a prevalence of
osteopenia that was double as compared to controls and a
prevalence of osteoporosis that was three times greater.
Previous studies identiﬁed a variety of factors that could
increase the susceptibility for bone loss in this population,
including inadequate diet and nutrition, long-term cortico-
steroid treatment, chronic inﬂammation per se, and genetic
factors as well.2,8–14,25,26 In the present study we observed
that, besides age, which applies to the general population,
small bowel involvement, previous surgical resections,
either colonic or involving the small bowel, duration of
disease for more than 15 years, and a low intake of vitamin
K were all positively associated with the presence of osteo-
porosis. The association with previous surgical resections
was particularly striking. Because these associations were
present both for small bowel as well as for colonic resec-
tions, we believe that these events may reﬂect a greater
severity of disease as opposed to reﬂecting the possibility
of a short bowel syndrome, as one might at ﬁrst think. Die-
tary intake of calcium and vitamin D was low in 50% of
CD patients included in the study, but most of these
patients were taking these as supplements, which was not
accounted for. This could be a reason for these variables
not having a discriminative power to distinguish between
patients having or not MBD.
With respect to steroids, the deleterious effects of
corticosteroids on trabecular bone mass are well docu-
mented in some studies, but conﬂicting evidence comes
from longitudinal and cross-sectional studies5,20,25,27,28 that
failed to show any correlation between the rate of bone
loss and steroid use. In a previous study, decreased bone
mass was already present at the time of diagnosis29 in
patients with CD. In the present study we observed that the
differences between T- and Z-scores in patients and con-
trols were more marked at the level of the lumbar spine
(trabecular bone) as compared with the hip (cortical bone),
which could suggest that these differences could be related
to steroid use. Due to the retrospective nature of our study,
previous steroid use was difﬁcult to quantify and three dif-
ferent approaches were used. No signiﬁcant association
was found between the presence of MBD evaluated either
as a T-score < 2.5 or a Z-score < 2.0 and previous ste-
roid use. Some authors also raise the hypothesis whether
steroid use is just a surrogate marker of more active and
chronic disease.9
Further supporting the role that chronic inﬂammation
per se induces a greater loss of bone mass, we also observed
that patients with active disease (HBI 4) and those with a
penetrating or stricturing disease, which are usually more
aggressive phenotypes, were also those with lower Z- and
T-scores, respectively. Azathioprine use showed a protective
effect, which also favors the hypothesis that controlling
TABLE 5. Multivariate Analysis for Patients Presenting
with a T-score < 2.5 or a Z-score < 2.0 Adjusting for
Age and Sex Distribution, Smoking Habits, BMI, or
Previous Use of Steroids
T-score < 2.5 Z-score < 2.0
OR, CI 95% OR, CI 95%
Age > 40 years old 7.91 (1.5–42.3)* 5.54 (0.5–53.5)
HBI  4 points 3.92 (0.9–17.2) 15.9 (1.2–188.9)*
Previous colonic
surgeries
8.85 (1.26–61.8)* 0
*P < 0.05.
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disease activity is beneﬁcial to prevent MBD. In contrast, no
effect was observed with the use of biological therapies but
the number of patients treated with these drugs is far too
small (n ¼ 13). The beneﬁcial effect of biologic therapies in
improving MBD in patients with CD has been recently
demonstrated.9
Because imbalances between pro- and antiinﬂamma-
tory cytokines inﬂuence mechanisms of both chronic
inﬂammation and bone reabsorption, previous studies have
examined the relation between genetic polymorphisms in
genes coding for these cytokines and increased propensity
for bone loss. Schulte et al14 showed that in patients with
CD, noncarriage of a 240 bp allele of the IL-1ra gene and
carriage of the 130-bp allele of the IL-6 gene were inde-
pendently associated with increased bone loss. In the pres-
ent study we only found signiﬁcant associations with
LTa252 A/G polymorphism, with carriers of the polymor-
phic allele presenting a higher risk for a T-score < 2.5.
Probably, either directly or indirectly by inﬂuencing disease
activity, SNPs at pro- and antiinﬂammatory cytokines are
potential promoter or protector factors with regard to MBD
in patients with CD.
One novel aspect of the present study was the associ-
ation found between low Z-scores and fat intake. Thus, we
observed that the amount of total fat as well as the type of
fat intake seemed to differ in patients with a Z-score lower
or higher than 2.0. In a previous study performed in this
same population, we observed that a high intake of total,
monounsaturated fat, as well as a higher ratio of n6/n3 pol-
yunsaturated fatty acids, were associated with a more
active disease.15 Fat intake is now regarded as a potent
immunomodulatory therapy in patients with CD30–35 either
by modulating eicosanoid synthesis, by altering cell mem-
brane ﬂuidity, cell signal transduction, or even gene expres-
sion. More interestingly, Gassull et al,30 in a randomized
controlled study performed in patients with active CD,
examined the effects of an n-6- versus an n-9-enriched diet
as compared with conventional therapy with steroids. The
study was prematurely stopped because, as opposed to
what was expected, patients treated with an n-9-enriched
diet had a much lower response rate compared with the
other two groups. Later on, we also observed that a high
intake of monounsaturated fat was associated with more
active disease.15 In the present study, although in univariate
analysis intake of monounsaturated fat was associated with
increased risk of presenting a Z-score lower than 2.0,
multivariate analysis did not show that fat intake was an
independent risk factor for MBD. Nonetheless, further stud-
ies are needed to clarify whether the amount and type of
fat intake might inﬂuence the prevalence of MBD in
patients with CD.
The results of the present study further support the
concept that MBD is a frequent complication of CD.
Besides age and low body weight, which are also risk fac-
tors in the general population, we observed that factors
associated with chronic, ongoing, and long-lasting inﬂam-
mation are probably major risk factors for this complica-
tion. To our knowledge this is the ﬁrst study that includes
a control group with similar age and gender distribution,
and which simultaneously analyzed demographic, genetic,
clinical, and nutritional factors as possible etiologic factors
in the pathogenesis of this complication.
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